Early findings from a publication between Scripps Research, IAVI, Dred Hutch, VRC, and other collaborators show encouraging results in hopes of boosting immunity against HIV. In the first- in-human test of the germline-testing strategy, the novel HIV vaccine approach showed promise, inducing broadly neutralizing antibodies (bnAbs), a rare antibody, previously indicated to protect against a wide range of HIV variants. Through the stimulation of the bnAb immune cells- precursor B cells, researchers have accomplished the first step to potential immunity against HIV.